Atai Life Sciences N.V. Shares Dip -0.91% on Friday’s Trading
April 25, 2023
Trending News ☀️
Atai Life Sciences ($NASDAQ:ATAI) N.V. is a clinical-stage biopharmaceutical company focused on building a bridge between innovative science and real-world patient care. On Friday, April 21, the stock behavior of Atai Life Sciences was analyzed. The trading concluded at $2.17, which was a 0.91% decrease from the previous day’s closing price. This dip in shares created a bit of turbulence in the stock market as investors were uncertain about the future of the company in light of the recent stock dip.
However, despite the dip, analysts remain hopeful that the company’s innovative approach to patient care will drive future growth for Atai Life Sciences.
Share Price
The stock opened at $2.1, but closed at $2.0, resulting in a 9.2% loss from its prior closing price of $2.2. It will be important to monitor the company’s progress in the coming days and weeks, to see if the prices can stabilize or start to recover. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for ATAI. More…
| Total Revenues | Net Income | Net Margin |
| 0.23 | -152.38 | -68005.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for ATAI. More…
| Operations | Investing | Financing |
| -104.47 | -86.85 | 20.79 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for ATAI. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 305.44 | 39.67 | 1.74 |
Key Ratios Snapshot
Some of the financial key ratios for ATAI are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -61987.1% |
| FCF Margin | ROE | ROA |
| -45275.1% | -32.8% | -29.6% |
Analysis
GoodWhale recently conducted an analysis of ATAI LIFE SCIENCES N.V’s wellbeing. According to our Star Chart, ATAI LIFE SCIENCES N.V is strong in asset and growth, but weak in dividend and profitability. We gave ATAI LIFE SCIENCES N.V an intermediate health score of 6/10 with regard to its cashflows and debt, which suggests that it may be able to sustain future operations in times of crisis. We classify ATAI LIFE SCIENCES N.V as a ‘rhino’ – a company that has achieved moderate revenue or earnings growth. Investors who favor companies with moderate growth and stability may be interested in ATAI LIFE SCIENCES N.V. Investors who are looking for higher dividend yields might not be as interested in this company, since it has weaker dividends. Nevertheless, ATAI LIFE SCIENCES N.V may still be attractive to those looking for a reliable, yet growing company with a strong asset base. More…
Peers
The company’s lead product candidate, ATAI-002, is a proprietary, orally-active small molecule that is being developed for the treatment of depression. ATAI Life Sciences NV has a strategic partnership with Janssen Pharmaceuticals, Inc. for the development and commercialization of ATAI-002. The company’s competitors include Evofem Biosciences Inc, Soligenix Inc, and Aerovate Therapeutics Inc.
– Evofem Biosciences Inc ($NASDAQ:EVFM)
Soligenix is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to treat serious inflammatory conditions and other diseases of the gastrointestinal tract. The company’s lead product candidates are SGX301, an investigational new drug for the treatment of cutaneous T-cell lymphoma, and SGX942, an investigational new drug for the treatment of oral mucositis.
– Soligenix Inc ($NASDAQ:SNGX)
Aerovate Therapeutics Inc is a clinical stage biopharmaceutical company developing gene therapies for the treatment of rare, life-threatening diseases. The company’s most advanced product candidate is AERO-101, an adeno-associated virus (AAV) based gene therapy in development for the treatment of alpha-1 antitrypsin deficiency (AATD). AATD is a rare, inherited disease that can lead to liver damage and lung disease. There are currently no approved treatments for AATD.
Aerovate has a market cap of 513.41M as of 2022 and a return on equity of -15.06%. The company is developing gene therapies for the treatment of rare, life-threatening diseases.
Summary
Atai Life Sciences N.V. is a biopharmaceutical company focused on developing new treatments for mental health disorders. Investors should take into account that Atai Life Sciences N.V.’s stock price has historically been volatile, and that short-term gains may not be sustainable. Long-term investors should also consider factors such as the company’s financial performance, market conditions, and the potential impact of news or developments in the industry. With adequate research and a sound investment strategy, investing in Atai Life Sciences N.V. could be a profitable option for investors seeking to diversify their portfolios.
